
Androlabs receives UK authorisation for new Testavan presentation
pharmafile | September 4, 2026 | News story | |Â Â Androlabs, Testavan, UK authorisation, hypogonadism, testosteroneÂ
Androlabs has received UK marketing authorisation for a new presentation of Testavan 4.6 mg/actuation transdermal gel for testosterone replacement therapy in adult men with confirmed hypogonadism.
Hypogonadism is a condition in which the body does not produce enough testosterone, potentially leading to symptoms including reduced libido, fatigue, decreased muscle mass and low mood. Testosterone replacement therapy aims to restore hormone levels and improve symptoms in affected patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) granted the authorisation on 5 May 2026. Testavan is indicated for adult men with testosterone deficiency confirmed by clinical features and biochemical testing.
The marketing authorisation is held by The Simple Pharma Company UK. Androlabs, which specialises in men’s health, will promote Testavan in the UK, with both companies part of the Tithonia Group.
The new authorisation expands Androlabs’ existing UK Testavan portfolio and, the company said, supports healthcare professionals involved in managing male hypogonadism.
Testavan 4.6 mg/actuation transdermal gel is a prescription only medicine. Androlabs said the authorisation does not represent a commercial launch, with details of product availability and launch timing to be announced separately.
Healthcare professionals are advised to consult the UK Summary of Product Characteristics for full prescribing information. Suspected adverse reactions should be reported through the MHRA Yellow Card Scheme.
Related Content

Androlabs and Majorelle expand testosterone therapy into France
Androlabs has partnered with French men’s health specialist Majorelle to commercialise Testavan, a testosterone replacement …

Mind the gap: men’s health and the need for progress
From prostate cancer to hormonal health, many areas of men’s health require more attention. As …

Chicago Judge overturns $140 million AbbVie AndroGel verdict
A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc. …





